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Background. In the Fluid Expansion as a Supportive Treatment (FEAST) trial, an unexpectedly high proportion of participants 
from eastern Uganda presented with blackwater fever (BWF).
Methods. We describe the prevalence and outcome of BWF among trial participants and compare the prevalence of 3 malar-
ia-protective red blood cell polymorphisms in BWF cases vs both trial (non-BWF) and population controls.
Results. Of 3170 trial participants, 394 (12.4%) had BWF. The majority (318 [81.0%]) presented in eastern Uganda and were the 
subjects of further analysis. BWF cases typically presented with both clinical jaundice (254/318 [80%]) and severe anemia (hemoglo-
bin level <5 g/dL) (238/310 [77%]). Plasmodium falciparum parasitemia was less frequent than in non-BWF controls, but a higher 
proportion were positive for P. falciparum histidine rich protein 2 (192/246 [78.0%]) vs 811/1154 [70.3%]; P = .014), suggesting 
recent antimalarial treatment. Overall, 282 of 318 (88.7%) received transfusions, with 94 of 282 (33.3%) and 9 of 282 (3.4%) receiving 
2 or 3 transfusions, respectively. By day 28, 39 of 318 (12.3%) BWF cases and 154 of 1554 (9.9%) non-BWF controls had died (P = 
.21), and 7 of 255 (3.0%) vs 13/1212 (1%), respectively, had severe anemia (P = .036). We found no association with G6PD deficiency. 
The prevalence of both the sickle cell trait (10/218 [4.6%]) and homozygous α+thalassemia (8/216 [3.7%]) were significantly lower 
among cases than among population controls (334/2123 [15.7%] and 141/2114 [6.6%], respectively), providing further support for 
the role of malaria.
Conclusions. We report the emergence of BWF in eastern Uganda, a condition that, according to local investigators, was rare 
until the last 7 years. We speculate that this might relate to the introduction of artemisinin-based combination therapies. Further 
studies investigating this possibility are urgently required.
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Historically, blackwater fever (BWF), a syndrome comprising 
acute intravascular hemolysis, fever, and the passage of dark 
or red-colored urine, has been recognized most commonly as 
a complication of recent or concurrent Plasmodium falciparum 
malaria infection in nonimmune expatriate adults living in 
Africa, where it was frequently complicated by severe anemia, 
jaundice, and renal failure [1, 2]. Although the etiology of 
BWF has been the subject of considerable speculation, it has 
frequently been linked to prior treatment with either quinine 
[3] or synthetic arylamino alcohol antimalarials [4] such as 
mefloquine and halofantrine, or to glucose-6-phosphate dehy-
drogenase (G6PD) deficiency [5]. A causal association between 
BWF and quinine is supported by its virtual disappearance 
from Africa following its replacement by chloroquine [6]. BWF 
has generally been considered a rare complication of malaria 
in African children [7], although a number of case reports and 
case series have variously linked the condition to the use of qui-
nine [7, 8] or to G6PD deficiency [9]. More recently, interest in 
BWF has been renewed following reports of a form of delayed 
hemolytic anemia with a more benign clinical course (postarte-
misinin delayed hemolysis [PADH]) that has been linked to the 
treatment of severe malaria with intravenous artesunate [10]. 
Initially described in travelers returning to Europe, PADH has 
also been described in case reports and small series in malar-
ia-endemic regions of Africa [11] and Southeast Asia [10, 12].
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Our recently reported multicenter trial of fluid resuscitation 
in African children with severe febrile illnesses and shock (Fluid 
Expansion as a Supportive Treatment [FEAST]) [13] included 
large subgroups with sepsis and malaria. Because hemoglobinu-
ria is included in the World Health Organization classification of 
severe malaria a question about dark urine was also included in 
the FEAST case report form. Here, we describe the prevalence, 
clinical features, and outcome of clinically reported dark urine 
(potential BWF) among children recruited to the FEAST trial.
METHODS
Patients and Methods
The methods and outcome of the FEAST trial have been described 
in detail previously [13]. In brief, FEAST was a pragmatic multi-
center trial of fluid resuscitation conducted among children pre-
senting to 6 East African hospitals in Kenya (1 center), Tanzania 
(1 center) and Uganda (4 centers) that enrolled 3170 children 
(aged 2 months to 12 years) presenting to hospital with severe 
febrile illnesses. Children with severe malnutrition, gastroenteri-
tis, trauma, burns, and nonmedical diagnoses were excluded.
Baseline and Follow-up Data and Sample Analyses
A structured clinical case report form was completed at admis-
sion by study clinicians. Hemoglobinuria was defined as a clini-
cal history of red, dark brown, or cola-colored urine. Admission 
blood samples were collected from recruited children, and whole 
blood and plasma were stored at –80°C for subsequent analysis. 
Plasma P. falciparum histidine rich protein 2 (pfHRP2), a sensitive 
marker of recent malaria infection, was quantified using methods 
described in detail previously [14]. The red blood cell polymor-
phisms sickle cell trait (hemoglobin [Hb] AS), sickle cell anemia 
(HbSS), the common African variant of α+thalassemia, and the B, 
A, and A– allelic variants of G6PD were typed by polymerase chain 
reaction [15] from DNA extracted using proprietary methods 
(Qiagen DNA Blood Mini Kits, Crawley, United Kingdom). With 
the exception of the study intervention, management of patients 
in the FEAST trial largely followed national guidelines. Children 
were monitored throughout admission. Hemoglobin estimation 
was repeated at 8 and 24 hours and at 28 days, and mortality was 
reported at 48 hours and 28 days postrandomization.
Population Controls
To compare the prevalence of red blood cell genetic polymor-
phisms among case subjects with hemoglobinuria to those in 
the general population, we recruited a second set of representa-
tive population controls from Mbale Regional Referral Hospital 
(MRRH) and Soroti Regional Referral Hospital (SRRH). 
Following appropriate consent, 2-mL samples of umbilical cord 
blood were collected from infants delivered consecutively on 
the maternity wards of MRRH and SRRH between 10 August 
2012 and 26 February 2013, along with data on ethnic group 
and place of residence.
Data Analysis
First, we described the demographic characteristics and clinical 
and laboratory features of trial participants by clinical site. In the 
2 sites with the highest prevalence of BWF (MRRH and SRRH, 
eastern Uganda) we then compared data from FEAST partici-
pants with a clinical history of hemoglobinuria (BWF cases) and 
any participant without BWF (controls). Nonnormally distrib-
uted data were log10 transformed before analysis. Continuous 
variables were compared using the Student’s t test, categorical 
variables using the χ2 test, and proportions by logistic regres-
sion. All statistical analyses were performed using Stata soft-
ware, version 11.0 (StataCorp, College Station, Texas).
The FEAST protocol was approved by the ethics commit-
tees of Imperial College, London; Makerere University and the 
National Council for Science and Technology in Uganda; the 
Kenya Medical Research Institute in Kenya; and the National 
Medical Research Institute in Tanzania, while ethical permis-
sion for the collection of blood and data from newborn controls 
was granted by the Mbale Research Ethics Committee, Uganda.
RESULTS
Demographic and Clinical Data Across Sites
The demographic characteristics, clinical features of severity, 
and mortality among FEAST trial participants, stratified by 
study site, are summarized in Table 1. The median age of par-
ticipants (24 months [interquartile range, 13–38 months]) was 
similar across sites. Overall, blood films were positive for P. fal-
ciparum malaria parasites in 1778 of 3170 (56.0%) participants, 
ranging from 40.7% (Kilifi, Kenya) to 73.1% (Lacor, northern 
Uganda). Hemoglobinuria and clinical evidence of jaundice 
were reported in 394 of 3170 (12.4%) and 1014 of 3164 (32.0%) 
participants, respectively. The majority of cases with BWF (391 
[99.2%]) presented in Uganda, with a particular focus in 2 hos-
pitals in eastern Uganda (MRRH and SRRH), where BWF was 
recorded in 180 of 1240 (14.5%) and 138 of 680 (21.8%) partic-
ipants, respectively while jaundice was recorded in 759 (61.2%) 
and 170 (27.0%) cases, respectively (Table 1).
Clinical and Laboratory Features of BWF in Eastern Uganda
The baseline characteristics of BWF cases (n = 318) and non-
BWF controls (n = 1552) at MRRH and SRRH are summarized 
in Table 2. Compared to controls, cases were significantly older 
(Table 2; Supplementary Figure 1) and were more likely to be 
male (P = .05). Cases had lower median hemoglobin concen-
trations (3.7 vs 7.1 g/dL; P < .0001), had a higher prevalence 
of severe anemia (77.0% vs 37.4%; P < .0001), were more likely 
to be hypothermic or clinically jaundiced or to have features 
of impaired perfusion, and displayed greater evidence of met-
abolic acidosis and acute renal injury. Both mean blood urea 
nitrogen (BUN) and the prevalence of hyperkalemia were 
>2-fold higher among cases than controls. Plasmodium falci-
parum parasitemia, detected either by rapid test (Optimal IT, 
Diamed, Switzerland), which can remain positive for some 
weeks after a malaria event, or microscopy, was significantly 
less common in cases than controls; however, pfHRP2 positivity 
was significantly more common (78.0% vs 70.3% in cases and 
controls, respectively; P = .014). Moreover, among those testing 
positive, geometric mean concentrations of pfHRP2 were lower 
in cases than in controls (200 vs 613 ng/mL, respectively; P < 
.0001), suggesting a higher rate of recent antimalarial treatment 
in cases compared with controls. Plasmodium falciparum was 
the only species of malaria parasites detected by either micros-
copy or by Optimal.
Urinalysis
For logistic reasons, urine samples were collected and tested 
at admission only from a subset of case (n = 100) and con-
trol (n = 366) children (Table 3). Moreover, the Multistix test 
(Multistix® 10 SG,  Siemens) was uninterpretable (and not 
reportable) when urine was profoundly black or cola-colored. 
Both hemolyzed and nonhemolyzed red blood cells were 
detected more frequently in cases than controls whereas pos-
itivity for urobilinogen, a marker of intravascular hemolysis, 
was low among both. Ketonuria and high specific gravity were 
common in both groups, likely reflecting the severity of the 
acidosis and hypovolemia. Because urinary tract infection was 
rarely recorded as a final diagnosis at 48 hours, we suspect 
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Diamed, Switzerland), which can remain positive for some 
weeks after a malaria event, or microscopy, was significantly 
less common in cases than controls; however, pfHRP2 positivity 
was significantly more common (78.0% vs 70.3% in cases and 
controls, respectively; P = .014). Moreover, among those testing 
positive, geometric mean concentrations of pfHRP2 were lower 
in cases than in controls (200 vs 613 ng/mL, respectively; P < 
.0001), suggesting a higher rate of recent antimalarial treatment 
in cases compared with controls. Plasmodium falciparum was 
the only species of malaria parasites detected by either micros-
copy or by Optimal.
Urinalysis
For logistic reasons, urine samples were collected and tested 
at admission only from a subset of case (n = 100) and con-
trol (n = 366) children (Table 3). Moreover, the Multistix test 
(Multistix® 10 SG,  Siemens) was uninterpretable (and not 
reportable) when urine was profoundly black or cola-colored. 
Both hemolyzed and nonhemolyzed red blood cells were 
detected more frequently in cases than controls whereas pos-
itivity for urobilinogen, a marker of intravascular hemolysis, 
was low among both. Ketonuria and high specific gravity were 
common in both groups, likely reflecting the severity of the 
acidosis and hypovolemia. Because urinary tract infection was 
rarely recorded as a final diagnosis at 48 hours, we suspect 
that the presence of leukocyte esterase (indicative of possible 
urinary tract infection) may have reflected contamination due 
to nonsterile sample collection techniques and/or delays in 
processing [13].
Red Blood Cell Genetic Polymorphisms
The prevalence of the red blood cell polymorphisms HbAS, 
HbSS, α+thalassemia, and G6PD deficiency among cases and 
among FEAST and population controls are summarized in Table 
4. Of particular note, the prevalence of HbSS was higher among 
cases than community controls (odds ratio [OR], 4.89; 95% con-
fidence interval [CI], 2.14–11.15; P < .001), providing a poten-
tial etiology in a small proportion (4.1%) of cases; however, no 
significant evidence was found to suggest that G6PD deficiency 
was a cause. Both HbAS and homozygous α+thalassemia were 
associated with protection from BWF (case-community control: 
OR, 0.26 [95% CI, .13–.50; P < .001] and 0.53 [95% CI, .25–1.11; 
P = .09], respectively), providing further evidence for the etio-
logical role of malaria in the current case series.
Follow-up and Outcome in Eastern Uganda
Mean hemoglobin level in cases remained significantly lower 
at 8 hours and 24 hours (Table  5). Overall, 282 of 318 cases 
(88.7%) received a transfusion compared with 700 of 1552 
controls (45.1%) (P  <  .0001). Moreover, a higher proportion 
Table 1. Summary of the Major Clinical and Laboratory Features of Severity Within the FEAST Study Sites
Site Mbale, Uganda Soroti, Uganda Lacor, Uganda Kampala, Uganda Kilifi, Kenya Teule, Tanzania
No. 1240 633 234 750 216 97
Demographic features
 Malaria endemicity Holoendemic Holoendemic Hyperendemic Hyperendemic Mesoendemic Mesoendemic
 Male sex 698 (56.3) 340 (53.7) 125 (53.4) 394 (52.5) 102 (47.2) 46 (47.4)
 Age, moa, median (IQR) 25 (14–39) 23 (14–36) 27 (16–36) 21 (12–39) 26 (11–46) 19 (12–39)
Clinical features of severity
 Respiratory distress 1222/1236 (99.0) 495/630 (78.6) 125 (53.4) 514/745 (69.0) 177 (82.0) 77/96 (80.2)
 Coma 241/1239 (19.5) 61/631 (9.7) 30 (12.8) 57 (7.6) 57 (26.4) 30 (31.0)
 Jaundice 759 (61.2) 170/630 (27.0) 28 (12.0) 55/747 (7.4) 1 (0.5) 1 (1.0)
 Dark urine 180 (14.5) 138/632 (21.8) 27 (11.5) 46/747 (6.2) 1 (0.5) 2 (2.0)
Laboratory data
 Malaria positive 699 (56.4) 388 (61.3) 171 (73.1) 381 (51.0) 88 (40.7) 51 (52.6)
 Hemoglobin level, g/dL, 
mean (SD)
6.5 (3.1) 6.5 (31) 7.1 (2.9) 8.1 (3.3) 8.5(2.6) 7.5 (3.1)
 Severe anemiab 639 (51.5) 340 (53.7) 96 (41.0) 197/743 (26.5) 34 (16.0) 37 (38.0)
 Hypoglycemiac 46/1134 (4.1) 19/618 (3.1) 21/223 (9.4) 29/710 (4.1) 9/214 (4.2) 12/95 (12.6)
 Lactate >5 g/dL 466/1135 (41.1) 301/627 (48.0) 90/210 (43.0) 222/727 (30.5) 55/214 (25.7) 45/95 (47.4)
 BUN >20 mmol/L 131/605 (21.7) 134/432 (31.0) 51/159 (32.1) 89/634 (14.0) 25/189 (13.2) 14/90 (15.6)
Outcome
 Mortalityd 115 (9.3) 58 (9.2) 38 (16.2) 63 (8.4) 21 (9.7) 20 (20.6)
Data are presented as No. (proportion) unless otherwise indicated. Denominators are indicated where data are missing.
Abbreviations: BUN, blood urea nitrogen; FEAST, Fluid Expansion as a Supportive Treatment; IQR, interquartile range; SD, standard deviation.
aCompleted months.
bHemoglobin level <5 g/dL.
cGlucose <2.5 mmol/L.
dAt 48 hours postrandomization.
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of cases than controls received a second and third transfusion 
(94/282 [33.3%] vs 107/700 [15.3%] and 9/282 [3.4%] vs 10/700 
[1.4%], respectively; P  <  .0001). Despite a greater number of 
severity features in cases, 48-hour mortality was similar to that 
of controls. By day 28, both case fatality and the proportion with 
severe anemia were marginally higher in cases than controls, 
whereas malaria infection remained significantly lower among 
cases (Table 5).
DISCUSSION
Historically, BWF has been considered a rare complication of 
malaria among children living in high-transmission settings 
[16–18]. More recently, however, a growing number of pediat-
ric case series have been published from both Africa [8, 19–22] 
and Oceania [23]. An early report from Lagos, Nigeria [19], 
described 20 children who presented to hospital with hemo-
globinuria that, in large part, the authors ascribed to G6PD 
deficiency (15/17 patients tested). Only 2 of these cases were 
malaria positive. In another study conducted in the same coun-
try [20], hemoglobinuria (defined by dipstick testing of urine) 
was described in 48 of 251 (19.1%) children presenting to hos-
pital with severe malaria, and was commonly associated with 
clinical jaundice (28/48 [58.3%]). In studies conducted in the 
Democratic Republic of Congo (DRC) [8] and Senegal [24], 
evidence was found to suggest that exposure to quinine might 
be an important etiological factor. Finally, in a careful evalua-
tion of children presenting with severe malaria in Papua New 
Guinea, O’Donnell and colleagues [23] found that although 
clinically apparent BWF was relatively rare (22/351 [6%]), evi-
dence of hemolysis was found on the basis of urine testing in a 
high proportion of children (115/351 [33%]).
In the current study, we observed notable geographic variation 
in the frequency of BWF. The majority of cases presented to 2 hos-
pitals in eastern Uganda (MRRH and SRRH), where a history of 
dark urine was elicited in 14.5% and 21.8%, respectively. FEAST 
trial participants from these hospitals therefore form the main 
focus of the current report. In this series, 77.0% of BWF cases 
were severely anemic (hemoglobin level <5 g/dL) and in keep-
ing with previous reports [8, 20] many (80.0%) were clinically 
jaundiced and showed laboratory evidence of renal impairment 
(BUN >20 mmol/L in 65.8%; Figure 1, Table 2). Renal impair-
ment was frequently described in previous reports of BWF [5, 
8, 25], and animal experiments have suggested that dehydration 
Table 2. Clinical Characteristics and Laboratory Parameters of Subjects 
With or Without a Clinical History of Dark Urine in Mbale and Soroti 
Hospitals, Eastern Uganda
Characteristics BWF Non-BWF
P 
Valuea
No. 318  1552
Demographic features
 Male sex 192 (60.4) 844 (54.4) .05
 Age, mo, median (IQR) 36 (26–56) 22 (13–36) <.0001
General clinical features
 Axillary temperature, °C, 
mean (95% CI)
37.4 (37.3–37.6) 38.2 (38.0–38.2) <.0001
 Hypothermia <36.0°C 35 (11.0) 97 (6.3) <.0001
 Clinical pallor 263 (83.0) 515/1551 (33.2) <.0001
 Clinical jaundice 254 (80.0) 673 (43.4) <.0001
Respiratory system
 Respiratory distress 275/317 (87.0) 1439/1546 (93.1) <.0001
 Crackles (pneumonia) 38 (12.0) 359 (23.1) <.0001
Circulatory system
 Tachycardiab 180 (57.0) 1085/1544 (70.3) <.0001
 Capillary refill time 
(≥3 sec)
170 (53.5) 348/1550 (22.5) <.0001
 Temperature gradient 224 (70.4) 968 (62.4) .006
 Weak pulse volume 92 (29.0) 361 (23.3) .032
 Decreased skin turgor 
(dehydration)
35 (11.0) 127 (8.2) .103
 Systolic blood pressure, 
mm Hg, median (IQR)
89 (82–97) 92 (85–101) .001
 Hypotensionc 28/312 (9.0) 92/1514 (6.1) .12
Nervous system
 Prostrate 239 (75.2) 824/1549 (53.2) <.0001
 Coma 27 (8.5) 274/1549 (17.7) <.0001
 Convulsions at admission 14 (4.4) 209/1549 (13.5) <.0001
Hematology and biochemistry
 Hemoglobin, g/dL, 
median (IQR)
3.7 (2.9–4.8) 7.1 (4.3–9.7) <.0001
 Lactate, mmol/L, median 
(IQR)
7.9 (3.7–13.2) 3.7 (2.2–7.7) <.0001
 Severe lactatemia 
(≥5 mmol/L)
204/309 (66.0) 560/1450 (38.6) <.0001
 Anion gap, mean (95% 
CI)
20.2 (19.4–21.0) 17.2 (16.8–17.6) <.0001
 Elevated anion gap (>11.0 
mEq/L)
75/172 (43.6) 153/783 (19.5) <.0001
 Glucose, mmol/L, median 
(IQR)
7.9 (5.9–10.2) 7.0 (5.6–8.8) .0011
 Sodium, mean (95% CI) 135.0 (134.3–135.8) 133.6 (133.2–133.9) .0007
 Potassium, mean (95% 
CI)
4.7 (4.5–4.8) 4.2 (4.1–4.3) <.0001
 Hyperkalemia 
(≥5.0 mmol/L)
32/189 (17.0) 69/836 (8.3) <.0001
 BUN, mmol/L, mean 
(95% CI)
33.0 (29.1–36.7) 14.2 (13.2–15.1) <.0001
 High BUN (>20 mmol/L) 123/187 (65.8) 140/847 (16.5) <.0001
Infection
 Malaria blood slide 
positive
147/300 (49.0) 938/1484 (63.2) <.0001
 pfHRP2 positive 192/246 (78.0) 811/1154 (70.3) .014
 Malaria blood slide or 
pfHRP2 positive
192/318 (60.4) 1148/1552 (74.0) <.0001
 Geometric mean pfHRP2, 
ng/mL (95% CI)
200 (149–269) 613 (541–695) <.0001
 HIV antibody positive 4/258 (1.6) 37/1160 (3.2) .022
Data are presented as No. (proportion) unless otherwise indicated.
Abbreviations: BUN, blood urea nitrogen; BWF, blackwater fever; CI, confidence interval; 
HIV, human immunodeficiency virus; IQR, interquartile range; pfHRP2, Plasmodium 
falciparum histidine-rich protein 2.
aP values reflect χ2 test for comparisons of proportions and Student’s t test for compari-
sons of means.
bPulse rate of >120 beats per minute (bpm) in children aged >5 years, >140 bpm in 
children aged 1–4 years, and >160 bpm in children aged <1 year.
cHypotension reflects systolic blood pressure <50 mm Hg, <60 mm Hg, and <70 mm Hg 
for children aged <1, 1–4, and >5 years, respectively.
may play an important etiological role in such patients [25]. In 
our current series, urine testing was positive for either hemolyzed 
or nonhemolyzed blood in the majority of patients tested. Taken 
together, this constellation of symptoms, signs, and clinical inves-
tigations is consistent with acute intravascular hemolysis.
The high frequency of BWF seen in our case series from east-
ern Uganda contrasts with the other sites involved in the FEAST 
trial. Moreover, it is also at odds with observations from the an 
open label randomised comparison of injectable Artesunate and 
Quinine in patients with severe falciparum malaria in Africa 
(AQUAMAT) trial of severe pediatric malaria, conducted 
between 2005 and 2010 in 11 centers across 9 African countries, 
in which BWF was reported in only 4% of >5000 patients and in 
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may play an important etiological role in such patients [25]. In 
our current series, urine testing was positive for either hemolyzed 
or nonhemolyzed blood in the majority of patients tested. Taken 
together, this constellation of symptoms, signs, and clinical inves-
tigations is consistent with acute intravascular hemolysis.
The high frequency of BWF seen in our case series from east-
ern Uganda contrasts with the other sites involved in the FEAST 
trial. Moreover, it is also at odds with observations from the an 
open label randomised comparison of injectable Artesunate and 
Quinine in patients with severe falciparum malaria in Africa 
(AQUAMAT) trial of severe pediatric malaria, conducted 
between 2005 and 2010 in 11 centers across 9 African countries, 
in which BWF was reported in only 4% of >5000 patients and in 
which only 2% presented with jaundice [26]. Of particular inter-
est, the authors of the latter study noted that in children without 
a history of BWF at admission, a higher proportion developed 
hemoglobinuria in the artesunate arm (30/2591 [1.2%]) than in 
the quinine (18/2597 [0.7%]) arm of the trial (OR, 1.69; 95% 
CI, .94–3.05; P = .076), although the numbers affected were rel-
atively few and reporting was limited to the period of hospital 
admission. The fact that our findings contrast with a number 
of previous malaria reports led us to question the cause for the 
high frequency of BWF seen in the current context.
In keeping with both historical and contemporary reports in 
children [8, 24], recent antimalarial treatment is a likely cause 
for BWF in our current case series. First, of the sites involved 
in the FEAST trial, MRRH and SRRH are situated in the areas 
of highest malaria transmission. Second, although a lower 
proportion of cases than controls were parasitemic, a higher 
proportion was positive for pfHRP2. Moreover, pfHRP2 con-
centrations were significantly lower in cases than controls, find-
ings that together suggest a high rate of recent malaria treatment 
among children presenting with BWF. Finally, a role for malaria 
is also supported by the protective associations of HbAS and 
α+thalassaemia, which were similar in degree to those previ-
ously described for severe malaria [27]. In contrast to several 
previous reports [5, 19], G6PD deficiency did not provide an 
explanation for the high frequency of BWF in our current case 
series. Similarly, although some cases had HbSS, a condition 
that is frequently complicated by both acute and chronic hemo-
lytic anemia and is often associated with clinical jaundice [28], 
this only provided a potential explanation for a small propor-
tion (4.1%) of BWF cases in our current report.
If, in our current case series, the occurrence of BWF is 
linked to malaria, it raises questions about why, in general, 
BWF has not been recognized as a major health problem in 
Table 3. Urine Dipstick Results in Patients With and Without a Clinical 
History of Blackwater Fever
Parameter
With
Blackwater Fever,
no./No. (%)
Without Blackwater 
Fever,
no./No. (%) P Value
Hemolyzed RBCs 51/94 (54.3) 46/314 (14.6) <.0001
Nonhemolyzed 
RBCs
10/89 (11.2) 19/297 (6.4) .3
High bilirubin 22/100 (22.0) 59/362 (16.3) .23
High urobilinogen 8/100 (8.0) 32/358 (9.0) .94
Ketones 57/100 (57.0) 144/364 (40) .001
Proteinuria 65/100 (65.0) 167/366 (45.6) .001
Nitrate 4/100 (4.0) 28/364 (7.7) .332
Glycosuria 1/100 (1.0) 5/366 (1.4) .551
Aciduria 69/100 (69.0) 271/359 (75.5) .63
High specific 
gravity
62/100 (62.0) 187/358 (52.2) .333
Leukocyte 
esterase
17/100 (17.0) 77/363 (21.2) .5
Not all parameters were reportable where the urine was too dark to interpret.
Abbreviation: RBC, red blood cell.
Table 4. Inherited Red Blood Cell Disorders in Cases, Hospital Controls, and Community Controls
RBC Polymorphism BWF Cases Non-BWF Controls aORa (95% CI) P Valuea
Community 
Controls aORb (95% CI) P Valueb
Hemoglobin S
 AA (normal) 199/218 (91.3) 996/1137 (87.6) Ref 1770/2123 (83.4) Ref
 AS (sickle cell trait) 10/218 (4.6) 68/1137 (6.0) 0.67 (.33–1.33) .25 334/2123 (15.7) 0.26 (.13–.50) <.001
 SS (sickle cell  
anemia)
9/218 (4.1) 70/1137 (6.4) 0.54 (.26–1.11) .09 19/2123 (0.9) 4.89 (2.14–11.15) <.001
α+Thalassemia
 Normal 126/216 (58.3) 609/1141 (53.6) Ref 1181/2114 (55.9) Ref
 Heterozygote 82/216 (38.0) 447/1141 (38.5) 0.89 (.65–1.21) .48 792/2114 (37.5) 0.93 (.69–1.25) .66
 Homozygote 8/216 (3.7) 85/1141 (7.9) 0.45 (.21–.96) .03 141/2114 (6.6) 0.53 (.25–1.11) .09
G6PD deficiency
 Normal 189/224 (84.4) 935/1061 (88.1) Ref 531/597 (88.9) Ref
 Deficientc 35/224 (15.6) 126/1061 (11.9) 1.37 (.91–2.05) .12 66/597 (11.1) 1.46 (.92–2.29) .10
Data are presented as the number with each condition/total number with data (proportion).
Abbreviations: aOR, adjusted odds ratio; BWF, blackwater fever; CI, confidence interval; G6PD, glucose-6-phosphate dehydrogenase; RBC, red blood cell.
aOdds ratios and P values for each genotype in cases vs hospital controls estimated by logistic regression, adjusting for sex and location.
bOdds ratios and P values for each genotype in cases vs community controls estimated by logistic regression, adjusting for sex and location.
cMale hemizygotes and female homozygotes for the G6PD A– polymorphism. Sample collection and storage was delayed at the beginning of the study, meaning that samples were not 
available for all participants.
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African children previously. Local investigators have indi-
cated that childhood BWF was rare at their hospitals until 
relatively recently, only having grown in importance during 
the last 7 years. Moreover, they report that some children are 
recurrently admitted with the triad of dark urine, anemia, 
and clinical jaundice and require frequent blood transfusions 
(P. O.-O. and C. E., personal communication). One possibil-
ity is a recent change in the local parasite population toward 
strains with a greater propensity to cause BWF, a hypothe-
sis advanced by others previously [5, 25, 29]. Of note, how-
ever, cases with BWF in our current series were significantly 
older than controls presenting without BWF (Supplementary 
Figure 1), an observation consistent with the hypothesis, pre-
viously proposed [24], that BWF in children might result from 
recurrent historic exposure to antimalarial drugs. In a series 
of 378 children with severe malaria in Kinshasa, DRC, a city 
with holoendemic malaria, 25% of cases had BWF, of which 
79% reported recent treatment with oral quinine and 6% had 
been treated with artemisinin-based combination therapies 
(ACTs) [22]. The authors suggested that the limited availa-
bility and higher cost of ACTs meant that quinine was being 
used increasingly as first-line treatment in uncomplicated 
malaria cases [30]. In Uganda, ACTs were introduced as first-
line treatment in 2006; the routine use of quinine has since 
become uncommon (P. O.-O., personal communication). We 
suggest, therefore, that ACTs are the agents most likely to 
have been used in the prior treatment of BWF patients in the 
current case series.
Of particular interest in this regard, a growing number of 
recent case reports from Europe have described hemolysis 
following intravenous therapy with artemisinin (summarized 
in [10]). In contrast to most historical reports of BWF, where 
hemolysis and hemoglobinuria occur soon after treatment, 
patients in these case series developed hemolysis 14–31 days 
following intravenous artesunate and showed signs of persis-
tent hemolytic activity for up to 6 weeks. Despite extensive 
investigations, no definitive cause for hemolysis has been iden-
tified [10]. This syndrome, labeled postartesunate noninfec-
tious delayed hemolysis and anemia (PANDHA), is reported 
to occur in up to 25% of artesunate-treated travelers [10, 31]. 
Further elucidation of the mechanism of PANDHA indicates 
that it may be due to delayed hemolysis of previously infected 
red blood cells that have been damaged by artesunate-induced 
parasite removal by the spleen. In a case series of 60 nontrans-
fused patients, 13 (22%) had delayed hemolysis [32], which 
was maximal after day 8 and greatest in those with the highest 
admission parasitemias, a distinct variant from the usual intra-
vascular hemolysis associated with the acute phase of malaria. 
With respect to our current study, injectable artesunate was not 
available in the community during the period of this study, so 
if linked to antimalarial treatments, our findings suggest that 
a broader spectrum of arteminsin compounds may result in 
PANDHA. Worldwide data on this possibility remain scarce 
[21, 31].
Our study has a number of limitations of which perhaps 
the most important was the fact that case ascertainment was 
based on a clinical history of dark urine collected from a 
parent. We did not inquire about recent antimalarial treat-
ments, and our study would have benefited from additional 
real-time laboratory investigations aimed at investigating 
the etiology more definitively. Urine testing was not possible 
in every child recruited and was only hemoglobin-positive 
Table 5. Hematological Indices and Outcome Over Time
Outcome Measure
With BWF
(n = 318)
Without BWF
(n = 1552) P Value
Hemoglobin at 8 h,  
g/dL, mean (95% 
CI)
5.8 (5.6–6.0) 7.4 (7.3–7.6) <.0001
Severe anemiab at 
8 h
103 (32.4) 189/1552 (12.2) <.0001
Hemoglobin at 24 h, 
g/dL, mean (95% 
CI)
6.5 (6.2–6.7) 7.7 (7.6–7.8) <.0001
Severe anemiab at 
24 h
56 (17.6) 92 (6.0) <.0001
Hemoglobin at day 
28, g/dL, mean 
(95% CI)
10.7 (10.4–10.9) 10.2 (10.1–10.3) .0009
Severe anemiab at 
day 28
7/255 (3.0) 13/1212 (1.0) .036
Malaria blood slide 
positive at 28 d
35/248 (14.1) 240/1186 (20.0) .026
Mortality at 48 h 33 (10.4) 138 (8.9) .40
Cumulative mortality 
at 28 d
39 (12.3) 154 (9.9) .21
Data are presented as No. (proportion) unless otherwise indicated. The percentages 
assume that all children are alive at 8 hours and 24 hours.
Abbreviations: BWF, blackwater fever; CI, confidence interval.
aHemoglobin level <5 g.
Figure 1. Severe anemia, jaundice, and raised blood urea nitrogen in 183 chil-
dren with blackwater fever. Only 183 of 318 (56%) children had complete data on 
all parameters.Abbreviations: BUN, blood urea nitrogen; CF, 48-hour case fatality.
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in 65% of readable samples. This observation might suggest 
that hemoglobinuria was not present at the time of testing, 
but might also be attributable to the paroxysmal nature 
of this condition (P. O.-O., personal communication). 
Nevertheless, the hematological picture (median hemo-
globin level 3.7  g/dL) is indicative of hemolysis, as is the 
high frequency of transfusion (88%) and repeat transfusion 
(36% of BWF cases receiving multiple transfusions). Despite 
this, severe anemia was significantly more common in cases 
than controls at 8 and 24 hours and at 28 days postadmis-
sion. This condition therefore is associated with a greater 
risk of severe and life-threatening morbidity and a marginal 
increase in the risk of longer-term mortality. Although the 
specific pathogenesis of PANDHA remains unclear, detailed 
investigation of patients in Europe did not implicate either 
drug-dependent or drug-independent hemolysis, although, 
to the best of our knowledge, a complement-mediated 
mechanism has yet to be investigated. A further limitation 
of the study is that we lack data on the prevalence of infec-
tions other than malaria. At the time the study was con-
ducted, facilities for bacteriological culture were limited at 
the Mbale and Soroti sites, and too few samples were cul-
tured to yield meaningful results.
CONCLUSIONS
Historically, BWF has not been considered a common com-
plication of malaria among children living in areas of high 
malaria transmission. Nevertheless, in the current report we 
have described a high frequency of BWF among participants of 
the FEAST trial. The majority of cases presented to 2 hospitals 
in eastern Uganda that are both situated within an area of very 
high malaria transmission. BWF has a high hidden burden of 
morbidity and mortality, with 90% requiring transfusions and 
>30% requiring multiple transfusions. Moreover, 28-day mor-
tality was 12%, and 3% of survivors remained severely anemic 
at this time point. We conclude that malaria and its treatment 
are important factors in the etiology of BWF in the study pop-
ulation and that this may be linked to the recent switch toward 
orally administered ACTs as first-line treatment for malaria 
within the region. Further studies investigating the incidence 
and etiology of childhood BWF in the context of ACTs are 
indicated.
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